S&P prescribes Akorn with triple-C rating amid possible bankruptcy

Akorn, a pharmaceutical company, has been downgraded to triple-C by S&P, following the announcement that Akorn has agreed plans to sell all its assets to repay debt as part of its standstill agreement extension

Subscriber-only article

This article is available only to Creditflux subscribers and free trial users within 30 days of publication.

Already a subscriber? Not logged in? Click here to login.

If you have not already done so,
you may request a FREE TRIAL by clicking here

This trial will give you:
  • 4-weeks' free online access to our
    most recent subscriber-only articles
  • Daily breaking news alert sent by email
  • A print copy of Creditflux

If you currently have a free trial, you will see this message when you try to view articles older than 30 days.

TAGS: Distressed debt Leveraged loans Performance North America